Asian Journal of Advances in Medical Science

3(1): 321-330, 2021

PEDIATRIC PHARMACOKINETIC: INFLUENCE AND IMPORTANCE

C. K. SAHOO[1], B. RAY[2*], AMIYAKANTA MISHRA[2], BIBHANWITA SATPATHY[3] AND CHINMAYA RATH[3]

[1]Department Pediatric, SCBMCH, Cuttack, Odisha, India.
[2]Post Graduate Department, CPS, Puri, India.
[3]GCP, Sambalpur, India.

AUTHORS' CONTRIBUTIONS

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Received: 04 August 2021
Accepted: 13 October 2021
Published: 16 October 2021

Review Article

ABSTRACT

Pharmacokinetic is the movement pattern of drug throughout the body. The study of Pharmacokinetic parameter is immense important during therapy which focus the accurate concentration of drug in plasma and its clearance. The study also suggests the appropriate doses and route of administration for rapid and successful action of Drug. In case of lower age group like pediatric community, the detail study of pharmacokinetic many times enables the safe use of drug as in case of Pediatric group many system like enzyme and excretion criteria are remaining in Underdeveloped condition. Population based models can also limit the sampling required from each individual by increasing the overall sample size to generate robust pharmacokinetic data. This review details key considerations in the design and development of pediatric Pharmacokinetic Parameter.

Keywords: Pharmacokinetics; ADME; pediatric drug development; physiology; Absorption; Distribution.

1. INTRODUCTION

Those patients that suffer from chronic ailments like polygenic disorder and brain disorder could need to take medicine daily for the remainder of their lives. At the opposite extreme ar those that take one dose of drug to alleviate Associate in Nursing occasional headache. The period of drug medical care is typically between these extremes. the way during which a drug is taken is termed a indefinite quantity program. Each the period of drug medical care and therefore the indefinite quantity program depend upon the therapeutic objectives, which can either be the cure, the mitigation, or the bar of sickness. as a result of all medicine exhibit undesirable effects like temporary state, waterlessness of mouth, epithelial duct irritation, nausea and cardiovascular disease, triple-crown drug medical care is achieved by optimally equalization the fascinating and undesirable effects. to attain best medical care, the acceptable "drug of choice" should be selected. This call implies Associate in Nursing correct diagnosing of the sickness, data of the clinical state of the patient, and a sound understanding of the pharmaco the rapeutic management of the sickness [1]. Pharmacokinetic measures, like space beneath the curve (AUC) and concentration at the utmost (Cmax) and parameters calculated from those measures, like clearance, half-life, and volume of distribution, mirror the absorption (A), distribution (D), and elimination (E) of a drug from the body. A drug will be eliminated by each metabolism (M) to 1 or additional active and inactive

**Corresponding author: Email: crabiswa@gmail.com;*

metabolites and excretion of the unchanged drug. the general set of processes is usually said as ADME, that ultimately controls general exposure to a drug and its metabolites when drug administration [2]. This general exposure, mirrored in plasma drug and/or matter concentrations, is mostly accustomed relate dose to each helpful and adverse effects. All medicine show inter- and intra-individual variance in pharmacokinetic measures and/or parameters. Variances will typically be substantial. within the paediatric population, growth and biological process changes in factors influencing ADME conjointly cause changes in pharmacokinetic measures and/or parameters. to attain terrorist group and Cmax values in kids almost like values related to effectiveness and safety in adults, it should be necessary to guage the pharmacological medicine of a drug over the whole paediatric age direct that the drug are used. The definitions of paediatric populations from the 1994 rule ar as follows: [3]! Neonate: birth to one month! Infant: one month to a pair of years! Children: a pair of to twelve years! Adolescent: twelve years to less than 16 year.

2. FACTORS AFFECTING PHARMA-COKINETIC STUDY

2.1 Age

Pharmacokinetic variability is particularly important at the extremes of age. This reflects differences in body composition and function. The weight related volume of distribution of water-soluble drugs (e.g.aminoglycoside antibiotics) is higher in neonates than in adults because of the greater proportion of water per kilogram of body weight. This means that if an adult and a neonate are each given a 5 mg/kg dose of a water-soluble drug such as gentamicin the maximum concentration will be around 16-20 mg/l in the adult and 10-11 mg/l in the neonate. In contrast, the relative volume of distribution of fat-soluble drugs, such as diazepam, is higher in the elderly.

Age also affects drug binding. The binding of drugs to albumin in the plasma is reduced in neonate and in the elderly [4].

The clearance of drugs is also affected by age. Renal function is low at birth and increases dramatically over the first two weeks of life. In later years, renal functions progressively decline and may be substantially reduced in elderly patients.

2.2 Body Weight

Many drug doses are based on body weight of the patient (expressed as mg/kg). If a drug is highly water soluble, it will have limited distribution into fat and its volume may, therefore, be better correlated with ideal body weight or lean body mass. In contrast total body weight may be more relevant for a drug that is highly lipid soluble. The use of total body weight to determine a drug dosage regimen may result in toxic effects if the patient is grossly obese [5].

2.3 Sex

Although differences in drug handling between males and females have been observed for a number of drugs, even after correcting for weights, such differences are considered to be too small to warrant a dose change. However, the doses can differ if the drug is being used for a sex specific indication e.g., buserelin for endometriosis or for prostate cancer.

2.4 Renal Function

Because many drugs are partially or mainly cleared by excretion through kidneys, deterioration in renal functions is one of the principal reasons for drug dosage adjustment.

The increase in elimination half-life may mean that a drug should be given less frequently to a patient with renal impairment. In contrast, the dose, rather than the dosage interval, is usually altered for a drug that has a long elimination half-life such as digoxin, because it is easier for the patient to take a daily dose than a dose on alternate days.

The influence of renal replacement therapy on drug clearance and dosage requirements is adversely affected by deteriorating renal function. Hemodialysis is an efficient way of removing many drugs, although the relatively short period of dialysis means the total amount of drug removed is often small [6].

2.5 Liver Function

Unlike in renal disease, where creatinine clearance estimates provide a reasonable guide to alterations in drug dosage requirements, indicators of hepatic disease, such as elevated liver enzymes, low serum albumin concentrations and clotting abnormalities, cannot be directly related to drug clearance. Nevertheless, patients with severe cirrhosis will often need reduced doses of hepatically cleared drugs to avoid toxicity. The increased exposure demonstrated in such patients may not simply be due to a decline in hepatic clearance but also, for some drugs, to an increase in bio availability caused by a reduction in first-pass metabolism. For example, the bio availabilities of morphine and labetalol have been reported to double in patients with cirrhosis.

Table 1. Genetic factors

Condition	Response	Abnormal Enzyme	Drugs Producing the Response
Slow and fast acetylation	Slow acetylators may show toxicity	N-acetyl transferase in LIVER	Isoniazid, Procainamide, Sulfonamides
Poor and extensive hydroxylation of Debrisoquine.	Poor metabolizers show toxicity.	Deficiency of one or more hepatic P-450 enzymes.	Phenformin. Dextromethorphan
Slow succinylcholine hydroxylase	Prolonged apnea	Cholinesterase in plasma	Succinyl choline

3. DRUG INTERACTIONS

Clinically significant drug interactions are often due to induction or inhibition of metabolizing enzymes or transporter proteins. However, interactions can also occur between drugs and food supplements or herbal remedies [7].

Interactions involving competitive inhibition often occur within two to three days whereas induction may take anything from hours to weeks. If the interacting drug has a long elimination half-life, the interaction may persist even after the drug has been discontinued. It is therefore important not only to consider potential interactions when two drugs are given together but also when one is stopped.

3.1 Other Factors

A range of other factors such as cardiac disease, respiratory disease and infection can lead to variability in drug concentration-time profiles. In addition, variations in adherence, which may take the form of missed doses, missed days or simply variations in the time of dosing, will lead to unequal dosage intervals and may affect the patient's response to therapy. This is of concern when the drug has a short elimination half-life.

3.2 Importance of Pharmacokinetic Study

1. A diagnostic tool
2 A means to evaluate the extent and rate of delivery of a drug
3 Prediction and understanding of adverse drug reactions
4 A means of predicting conditions not experimentally tested, such as dosage levels, time, etc.
5 A means of predicting biological levels in tissues not sampled
6 A means of comparing animals within species or among species
7 A means of quantitating biological variability
8 A means of mathematically describing a biological system [8].

4. INTERACTIONS AND ADVERSE REACTIONS

INTPharmacokinetic interactions may occur during the absorption phase, as well as during the distribution and the elimination phase. If such interactions are suspected on the basis of animal data, expected on the basis of the physico-chemical or pharmacological properties of the substance or similar compounds (i.e. protein binding, enzyme induction), or observed during (pre)clinical studies, the pharmacokinetic changes due to such interactions should be measured and, whenever possible, the mechanisms elucidated (e.g. enzyme induction, competition for renal elimination sites, etc.).

Certain types of adverse reactions are due to unusual genetic pharmacokinetic variations; though it will rarely be possible to study such aberrant behavior in a prospective manner every effort must be put into elucidating the pharmacokinetic mechanism(s) if there is any reason to suspect that the adverse reaction is caused by the altered pharmacokinetics of the substance [9].

Pharmacokinetic Properties to be studied



5. METHODOLOGY AND DESIGN STUDY

5.1 Study Design

In general, pharmacokinetic studies in the pediatric population should determine how the dosage regimen in the pediatric population should be adjusted to achieve approximately the same level of systemic exposure that is safe and effective in adults. Depending on the intended use of a drug in the pediatric population, studies should be performed in all pediatric age groups to allow dose adjustment within an individual over time. For drugs with linear pharmacokinetics in adults, single-dose studies often allow adequate pharmacokinetic assessment in the pediatric population.

Any nonlinearity in absorption, distribution, and elimination in adults, and any duration-of-effect related changes would suggest the need for steady state studies in the pediatric population.

Because there may be limited information on the safety of the dose to be administered to a neonate or infant, doses in initial studies require careful consideration. Factors for consideration include

(1) The relative bioavailability of the new formulation compared to the adult formulation;
(2) The age of the pediatric population;
(3) The therapeutic index of the drug;
(4) Pharmacokinetic data from the adult population; and
(5) Body size of the pediatric study population.

Initial doses should be based on mg/kg of body weight or mg/m2 of body surface area, extrapolated from adult doses. Knowledge of ADME in an adult population should be combined with an understanding of the physiologic development of the intended pediatric study population to modify the initial dose estimate. Consideration should initially be given to administering a fraction of the dose calculated from adult exposure, depending on the factors mentioned above and depending on whether there is any pediatric experience. Subsequent clinical observations and prompt assay of biological fluids for the drug and/or its metabolites should permit subsequent dose adjustment [10].

5.2 Scheme of Administration

Both single-dose and multiple-dose studies should be performed within the recommended dose range and dose intervals. Multiple-dose studies should be, whenever possible, continued long enough to establish steady-state concentrations of the substance, and for such steady-state levels, their dose dependence and variability should be determined. Accumulation kinetics of the substance predicted from the kinetic constants obtained from single-dose studies should be verified experimentally: different doses should be included in one study to determine dose dependence.

5.3 Subjects

5.3.1 Initial studies

Initial studies are generally performed in a restricted number of fasting, healthy, volunteers, in well-defined and controlled conditions. When the substance carries too serious a risk to healthy volunteers (e.g.,cytostatic), they are conducted in patients suffering from diseases for which the substance is considered to be indicated.

5.3.2 Further studies in patients

Further studies should be conducted in patients suffering from diseases for which the substance is claimed to be indicated. The relation between dose, plasma concentration and therapeutic effect, where this is feasible, should be studied. Particularly, it should be established that the pharmacokinetic behavior of the substance in patients corresponds to that in healthy subjects. The full range of kinetic studies need only be repeated in patients if studies indicate that the pharmacokinetics in this group differ from those in healthy volunteers.

5.3.3 Influence of various patho-physiological states

It is very useful to know the kinetics of substances in a very large number of patho-physiological situations; however, this knowledge requires multiple, long and expensive studies which cannot all be performed before authorization [11].

5.4 Methodology [12]

The quality of pharmacokinetic analysis depends on the quality of the experimental data that serve as input for like analyses. There are two meat-and-potatoes approaches for performing pharmacokinetic evaluations, the standard pharmacokinetic approach and the population pharmacokinetic (PK) approach. It involves administering either single or multiple miracle drugs of a physic to a like small (e.g., 6-12) group of subjects with like frequent blood and sometimes urine sample collection. Samples are collected over specified intervals, chosen predicated on enthrallment and disposition half- lives, and

thereafter assayed for enthrallment, either total and/ or unconfined, of physic and pertinent metabolites, if present. Both model independent and model-dependent approaches can be used to establish pharmacokinetic measures, parallel as AUC and Cmax and pharmacokinetic parameters, parallel as permission, volume, and half- life, which are descriptive of enthrallment over time. Data are normally expressed as the means of the pertinent measure and/ or parameter andinter-individual frictions. It's important in this approach to include enough subjects to give a reasonable estimate ofvariability. However, either at the single miracle drug or after multiple miracle drugs, some understanding ofintra-individual variability in pharmacokinetic parameters may be made, If replicate administration of the physic is handed for. B. Population PK Approach An alternate, and possibly preferable, approach in beaucoup pediatric situations is the population PK approach, or study. This approach relies on isolated (light) sample of blood from a larger population than would be used in a standard pharmacokinetic study to determine pharmacokinetic measures and/ or parameters. The population PK approach is generally used in cases being given the medicament therapeutically. It poses slight issues ofnon-therapeutic studies in children, who are considered a vulnerable population. Another advantage of the population PK approach in pediatric populations, where blood collection is sometimes dodgy, is that it allows for isolated sample, sometimes as beaucoup as 2-4 samples per subject, with sample collection carried out normally during routine clinic visits and performed together with other blood and/ or urine sample. Because a like large number of cases are studied and samples can be collected at colored times of day and hourly over time in a given subject, estimates of both population and individual means, as well as estimates of intra-andinter-subject variability can be bagged if the population PK study is duly designed. Pharmacodynamic endpoints also can be measured when collecting blood and/ or urine samples so that population PK studies can also deliver some understanding of absorption- response cooperations for both efficaciousness and poison [13]. Special considerations for a population PK study include the following 1. Where possible, the study population, sample size, and age distribution should be good, either in a single study or several studies, to give information on all pediatric age groups for which the medicine is intended. 2. If other factors affecting the pharmacokinetics of the medicine are to be studied (e.g., the effect of a coexistent medicine or the presence or absence of a distemper), sufficient figures of subjects with and without the factor should be included in the study. 3. The sample scheme should be precisely planned to carry the maximum information using the lowest number of samples. 4. Some knowledge of the pharmacokinetics of the medication to be delved from foregoing grown-up or pediatric experience may be used to develop the sample scheme. C. Sample Collection Pharmacokinetic PK studies should be conducted in pediatric populations with especially close attention to safety. Volume and frequence of blood pullout are hourly of concern in pediatric studies. Blood samples can be carried by direct venipuncture or through the use of intravascular catheters. Because repeated venipuncture may create pain and bruising at the pinhole location, use of intravascular catheters should be considered. Given the difficulty of collecting blood samples in the pediatric population, special approaches to allow optimal times of sample collection may be useful. Volume and frequence of blood sample can be minimized by using micro-volume medication assays and niggardly- sample manners, separately. These matters are especially apropos when studying babes Mod assay manners allow small sample volumes to be used to determine medication attention, but data quality may be affected if sample volume is lacking to allow for esampling for unusual results. Blood samples collected should come from the circulating blood volume and not from funds created by catheters or other bone. The time of sample collection, proper sample transportation and depot, and sample direction manners should be well established. The collection of fluids matching as cerebral spinal fluid (CSF) or bronchial fluids are invasive procedures that should only be used when clinically necessary. Noninvasive selection procedures, matching as urine and spit collection, may serve if the correlation with blood and/ or tube situations has been substantiated [14]. D. Sample Analysis The well-founded technique used to quantify the specific and metabolite (s) in the natural fluid of interest should be accurate, precise, sensitive, specific, and reproducible. Pat, the technique should be like swift, readily adaptable, and use only tiniest sample volumes. E. Covariates The following covariates should normally be reaped for each subject height, weight, body veneer area, aborting age and birth weight for bambinos, and relative laboratory tests that reflect the function of organs responsible for specific elimination. Concurrent and recent specific therapeutic should also be recorded. The relationship between these parameters and the pharmacokinetics of the specific of interest should be examined using suitable statistical tactics and study designs. F. Data Analysis A general aspiration of a pediatric population PK study is to allow acclimation in pediatric lozenges to achieve analogous systemic exposure measures and/ or parameters to those observed in grown-ups. Conclusions may be grounded on a comparison of log- converted means for

pharmacokinetic measures and/ or parameters of interest. In certain examples, correlation using suitable statistical approaches may be useful in defining changes in pharmacokinetic measures and/ or parameters with growth and development and other covariates.

H. Presentation and evaluation of the results

In summarizing data obtained from more than one subject, it is usually preferable to analyze individual data and at a later stage to average the pharmacokinetic constants so obtained. Proper statistical analysis of the data obtained should be made and the inter- and intraindividual variations estimated, in at least some of the studies where the number of subjects is large enough.

5.5 Labeling Statements

The labeling for a product should reflect the data pertaining to the effect of age and/or development on the pharmacokinetics and pharmacodynamics (if known) obtained from the studies conducted. If appropriate, this information may be included in the clinical Pharmacology. .An effort should be made to convey this information on a mg/kg basis, as this is the most common way pediatricians calculate dosing for children.

5.6 Precautions

The Pediatric Use section should convey information on safety and activity of the drug in children according to age, even if the information is limited by small number of subjects or by brief periods of observation. These limitations should be clearly stated in this section of the label. [15]

5.7 Ethical Considerations

Both investigators and institutional review boards familiar with clinical trials in children should assist in ensuring practices that safeguard the child participant. Particular attention needs to be directed to guidance on good clinical practice, which contains a section on nontherapeutic trials in children. As noted above, population PK approaches may mitigate several problems in conducting pediatric pharmacokinetic studies.

The issues of consent and assent for pediatric patients enrolled in clinical trials are necessary. Review board regulations apply. The standards of the country in which the study is performed must be met.

General properties:

- dC/dt = -K[C]
- A plot of the log[conc] -vs- time is linear.
- slope of the line = -Kel / 2.303
- The half-life of the drug remains constant throughout its excretion

COMPARTMENTS:

- One-Compartment Kinetics: Kinetics is calculated based on the assumption that the drug is distributed to one uniform compartment.
- One compartment kinetics implies that the drug has a rapid equilibrium between tissues and the blood, and that the release of the drug from any tissues is not rate-limiting in its excretion.
- This occurs ideally with IV infusion.
- Multi-Compartment Kinetics: Most drugs follow multi-compartment kinetics to an extent [16].

Clearance: The apparent volume of blood from which a drug is cleared per unit of time.

Clearance of drug = (Vd)x(Kel)



In first-order kinetics, drug is cleared at a constant rate. A constant fraction of the Vd (vol. of distribution) is cleared per unit time. The higher the Kel, the higher is that fraction of volume, the more rapid is its clearance.

Drug Clearance of 120 ml/min --> drug is cleared at the same rate as GFR and is not reabsorbed. Example = inulin

Apparent volume of distribution: The apparent volume of distribution (Vd) is that the volume of fluid that the drug would occupy if it were equally distributed through that volume at the concentration measured within the plasma (central compartment). The volume of distribution is solely hypothetic Associate in Nursingd doesn't represent an actual physical volume within the animal. Indeed, once a drug binds preferentially to tissues at the expense of plasma (e.g., a drug that's extremely oleophilic and partitions into fat), the plasma concentration are going to be very low. this can end in a large apparent volume of distribution, that will be larger than the particular volume of the animal itself (>1L/kg). it's attainable for Cupid's itch to be on the brink of a recognizable volume, like plasma volume (~0.05 L/kg), further cellular fluid (~0.2 L/kg), or total body water (~0.7 L/kg). this might happen if the drug is uniformly distributed in one in all these "compartments" however this can be rare. The Cupid's itchn is largely a convenient methodology for describing however well a drug is faraway from the plasma and distributed to the tissues. However, it does not give any specific info regarding wherever the drug is or whether or not it's targeted during a explicit organ. an oversized volume of distribution implies wide distribution, or in depth tissue binding, or both. Conversely, ionized medication that ar treed in plasma, can have little volumes of distribution [17].

AUC (area-under the-curve): This is the overall amount of drug in the bloodstream after a dose. AUC studies are often used when researchers are looking for drug-drug or drug-food interactions. The way to get an AUC involves collecting many blood samples (usually every one or two hours) right after a person takes a dose up until the next dose is due. In each blood sample, the concentration of the drug is measured. Then all the drug concentrations are put onto a graph based on the time after the dose that they were collected. A curve is made by connecting the points on the graph. The AUC for that drug is then calculated as the area under this drug concentration curve. An AUC study contains a lot of information about PK. It is probably the best way to understand how people handle a drug (PK).

Cmax (maximum concentration): This is the highest concentration of drug in the blood that is measured after a dose. Cmax usually happens within a few hours after the dose is taken. The time that Cmax happens is referred to as Tmax.

Cmin or trough (pronounced "troff") (minimum concentration): This is the lowest concentration of the drug in the blood that is measured after a dose, trough concentration (Cmin). It happens right before a patient takes the next usual dose [18].

Bioavailability: The proportion of orally-administered drug that reaches the target tissue and has activity.

$$t_{1/2} = \frac{\ln(2)}{K_{el}} = \frac{0.693}{K_{el}}$$

- AUC_{ORAL} = Area under the curve. The total amount of drug, through time, that has any activity when administered orally.
- AUC_{IV} = Area under curve. The total amount of drug, through time, that has any activity when administered IV. This is the maximum amount of drug that will have activity.
- 100% Bioavailability = A drug administered by IV infusion.

Half-life: Half-life (t ½): this can be the quantity of your time it takes for the drug concentration within the blood to say no by [*fr1]. The half-life is among the foremost necessary PK measurements for the way typically a drug should be treated (once-a-day or twice-a-day, etc). The half-life is reciprocally proportional to the Kel, constant of elimination. The higher the elimination constant the shorter the half-life [19].

Steady-state: this suggests that someone has been on a drug for enough time (usually one to 2 weeks) in order that the drug concentration isn't increase within the blood any longer. The time it takes to induce to steady-state depends on the half-life of the drug. A drug gets to steady state in regarding 5 half-lives. As associate degree illustration, before a patient reaches steady-state, every further dose could also be building the drug up within the body thus every dose would be giving a better Cmax, Cmin, and AUC. But, at steady-state, each dose would offer an equivalent Cmax, Cmin, and foreign terrorist organization within the patient as a result of it's not increase from now on. Steady-State Concentration (CSS): The plasma concentration of the drug once it's reached steady state. Once one half-life, you've got earned five



hundredth of CSS. Once 2 half-lives, you've got earned seventy fifth, etc. Thus, once four or five half-lives, you've got earned~98% of CSS that is shut enough for sensible functions.

Loading Dose: once a drug incorporates a long half-life, this can be the way to induce to CSS a lot of quicker. Loading Dose = double the regular dose, as long as we tend to square measure giving the drug at an equivalent interval because the half-life.

Renal Disease: Renal sickness will increase the time to achieve steady-state concentration. urinary organ sickness-- longer half-life --- longer time to achieve steady-state. Renal sickness means that the drug isn't cleared as quickly - the drug can have a better CSS: mwe must always modify the dose downward to accommodate for the slower clearance. This study provides the primary information on the population pharmacological medicine of Theobid in medicine patients receiving ECMO. The pharmacokinetic model was developed through information obtained from continuous blood vessel infusions of Slo-Bid [20].

6. CONCLUSION

Estimation of Pharmacokinetic Parameter is highly challenging in therapy, particularly for Pediatric group.Measurment of Plasma concentration is immense important during any chronic therapy for lower age group. So process, Protocol and Instrumentation must be develop for the Purposeful study.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Aslan YY, Koca LL, Mutlu MM, et al. Apopitotic effects of dopamine and dobutamine on neutrophils of premature neonates. J Matern Fetal Neonatal Med. 2011;24:1155–1158. DOI:10.3109/14767058.2010.545914
2. Banner W, Vernon DD, Minton SD, Dean JM. Nonlinear dobutamine pharmacokinetics in a pediatric population. Crit Care Med. 1991;19:871–873.
3. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. BMJ. 2000;320:79–82.

4. Coté CJ, Kauffman RE, Troendle GJ, Lambert GH (1996) Is the "therapeutic orphan" about to be adopted? Pediatrics 98:118–123
5. Driscoll DJ. Use of inotropic and chronotropic agents in neonates. Clin Perinatol. 1987;14: 931–949.
6. EMA. Revised priority list for studies into off-patent paediatric medical products. European Medicines Agency, London, EMA/480197/ 2010. 2020;1–8.
7. Filippi L, Pezzati M, Poggi C, et al. Dopamine versus dobutamine in very low birthweight infants: endocrine effects. Arch Dis Child Fetal Neonatal Ed. 2077;92:F367–F371. DOI:10.1136/adc.2006.098566
8. Greenough A, Emery EF. Randomized trial comparing dopamine and dobutamine in preterm infants. Eur J Pediatr. 1993;152:925–927
9. Hamamichi Y, Ichida F, Tsubata S, et al. Dobutamine stress radionuclide ventricul-ography reveals silent myocardial dysfunction in Kawasaki disease. Circ J. 2002;66:63–69.
10. Jose AB, Niguidula DF, Botros S, et al. Hemodynamic effects of dobutamine in children; 1981.
11. Kates RE, Leier CV. Dobutamine pharmaco-kinetics in severe heart failure. Clin Pharmacol Ther. 1978;24:537–541.
12. Lorenz JM, Kleinman LI, Ahmed G, Markarian K. Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics. 1995;96:484–489.
13. Lorenz JM, Kleinman LI, Ahmed G, Markarian K. Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics. 1995;96:484–489.
14. Osborn D, Evans N, Kluckow M. Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr. 2002;140:183–191
15. Perkin RM, Levin DL, Webb R, et al. Dobutamine: a hemodynamic evaluation in children with shock. J Pediatr. 1982;100:977–983
16. Razavi RS, Baker A, Qureshi SA, et al. Hemodynamic response to continuous infusion of dobutamine in Alagille's syndrome; 2001.
17. Rozé JC, Tohier C, Maingueneau C, et al. Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child. 1993;69:59–63. DOI:10.1136/adc.69.1_Spec_No.59
18. Sakata Y, Iijima T, Yoshida I, et al. Effects of dopamine and dobutamine on systemic hemodynamics and myocardial metabolism in; 1991.
19. Trifonova NA, Ismail-Zade IA, Michelson VA. Value of dobutamine in children surgically treated for portal hypertension. Apropos of 23 cases. Cah; 1994.
20. Yan M, Webster LT, Blumer JL (2002) 3-O-methyldobutamine, a major metabolite of dobutamine in humans. Drug MetabDispos. 2002;30:519–524. DOI:10.1124/dmd.30.5.519